Ares Life Sciences, a reported €1 billion (US$1.27 billion) investment vehicle established earlier this year by the Bertarelli family, former majority owners of Serono SA, has acquired a 10.6 percent stake in specialty pharmaceuticals firm Santhera Pharmaceuticals AG in return for CHF15.9 million (US$13.5 million). (BioWorld International)